They have been doing good things all along. Same pathway as Trofinetide which has proven successful.
The SP will recover at some point if they just keep relentlessly creating value. As soon as Trofinetide passes P3 it will be happy days - it will also add a lot of credibility to Neuren and their technology which should see more support for NNZ-2591 and perhaps an earlier licencing deal. Again you would have to think NNZ-2591 meets the strategic objectives of Acadia in NA.
Ann: Neuren submits 3 NNZ-2591 Orphan Drug applications to FDA, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.85 |
Change
-0.110(0.85%) |
Mkt cap ! $1.598B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.05 | $12.53 | $6.559M | 511.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1657 | $12.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.85 | 6303 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |